Beneficial effects of systemic immunoglobin in experimental membranous nephropathy

Kidney International

Volumn 50, Issue 6, 1996, Pages 2054-2062

  Nangaku, Masaomi ^b   Pippin, Jeff ^b   Richardson, Catherine A ^b   Schulze, Matthias ^b   Young, Bessie A ^b   Alpers, Charles E ^b   Gordon, Katherine L ^b   Johnson, Richard J ^b   Couser, William G ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEYMANN NEPHRITIS; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 0029949550     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.529     Document Type: Article

References (69)

1. COGGINS CH, FROMMER JP, GLASSOCK RJ: Membranous nephropathy. Semin Nephrol 2:264-273, 1982
2. COUSER WG: Glomerular diseases, in Textbook of Medicine. A Systematic Approach, edited by STEIN J, Boston, Little Brown and Co., 1986
3. MALLICK MP, SHORT CD, MANOS J: Clinical membranous nephropathy. Nephron 34:209-219, 1983
4. NOEL LH, ZANETTI M, DROZ D, BARBANEL C: Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med 66:82-90, 1979
5. ROW PG, CAMERON JS, TURNER DR, EVANS DJ, WHITE RH, OGG CS, CHANTLER C, BROWN CB: Membranous nephropathy. Long term follow up and associated with neoplasia. Q J Med 45:207-239, 1975
6. SYSTEM USRD: USRDS 1994 Annual Data Report. Bethesda, The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1994
7. CAMERON JS: Membranous nephropathy and its treatment. Nephrol Dial Transplant 7:S72-S79, 1992
8. AUSTIN IHA, ANTONOVYCH TT, MACKAY K, BOUMPAS DT, BALOW JE: Membranous nephropathy. NIH conference. Ann Intern Med 116:672-682, 1992
9. REMUZZI G, SCHIEPPATI A, GARATTINI S: Treatment of idiopathic membranous glomerulopathy. Curr Opin Neplirol Hypertens 3:155-163, 1994
10. FUIANO G, STANZIALE P, BALLETTA M, SEPE V, MARINELLI G, COMI N, ESPOSITO A, ANDREUCCI VE: Effectiveness of steroid therapy in different stages of membranous nephropathy. Nephrol Dial Transplant 4:1022-1029, 1989
11. DONADIO JVJ, HOLLEY KE, ANDERSON CF, TAYLOR WF: Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int 6:431-439, 1974
12. CATTRAN DC, DELMORE T, ROSCOE J, COLE E, CARDELLA C, CHARRON R, RITCHIE S, TORONTO GLOMERULONEPHRITIS GROUP: A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 320:210-215, 1989
13. CAMERON JS, HEALY MJR, ADU D: The Medical Research Council trial of short term high dose alternate day prednisolone in idiopathic membranous nephropathy with a nephrotic syndrome in adults. Q J Med 74:133-156, 1990
14. PONTICELLI C, ZUCCHELLI P, IMBASCIATTI E, CAGNOLI L, POZZI C, PASSERINI P, GRASSI C, LIMIDO D, PASQUALI S, VOLPINI T, SASDELLI M, LOCATELLI F: Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310:946-950, 1984
15. MATHIESON PW, TURNER AN, MAIDMENT CGH, EVANS DJ, REES AJ: Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 2:869-872, 1988
16. COUSER WG, ABRASS CK: Pathogenesis of membranous nephropathy. Annu Rev Med 39:517-530, 1988
17. COUSER WG: Mediation of immune glomerular injury. J Am Soc Nephrol 1:13-29, 1990
18. COUSER WG: Pathogenesis of glomerulonephritis. Kidney Int 44(Suppl 42):S19-S26, 1993
19. KERJASCHKI D, SCHULZE M, BINDER S, KAIN R, OJHA PP, SUSANI M, HORVAT R, BAKER PJ, COUSER WG: Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy. J Immunol 143:546-552, 1989
20. SAVIN VJ, JOHNSON RJ, COUSER WG: C5b-9 increases albumin permeability of isolated glomeruli in vitro. Kidney Int 46:382-387, 1994
21. JAYNE DR, DAVIES MJ, FOX CJ, BLACK CM, LOCKWOOD CM: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337:1137-1139, 1991
22. LIN CY, HSU HC, CHIANG H: Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 53:303-310, 1989
23. ROSTOKER G, DESVAUX-BELGHITI D, PILATTE Y, PETIT-PHAR M, PHILIPPON C, DEFORGES L, TERZIDIS H, INTRATOR L, ANDRE C, ADNOT S, BONIN P, BIERLING P, REMY P, LAGRUE G, LANG P, WEIL B: High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura. Ann Intern Med 120:476-484, 1994
24. PALLA R, CIRAMI C, PANICHI V, BIANCHI AM, PARRINI M, GRAZI G: Intravenous immunoglobulin therapy of membranous nephropathy: Efficacy and safety. Clin Nephrol 35:98-104, 1991
25. DWYER JM: Manipulating the immune system with immune globulin. N Engl J Med 326:107-116, 1992
26. BALLOW M: Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 68:1430-1436, 1991
27. RONDA N, HUREZ V, KAZATCHKINE MD: Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang 64:65-72, 1993
28. MAGEE JC, COLLINS BH, HARLAND RC, LINDMAN BJ, BOLLINGER RR, FRANK MM, PLATT JL: Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 96:2404-2412, 1995
29. GAUTREAU C, KOJIMA T, WOIMANT G, CARDOSO J, DEVILLIER P, HOUSSIN D: Use of intravenous immunoglobulin to delay xenogeneic hyperacute rejection. Transplantation 60:903-907, 1995
30. FRANK MM, BASTA M, FRIES LF: The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 62:882-86, 1992
31. BASTA M, KIRSHBOM P, FRANK MM, FRIES LF: Mechanism of therapeutic effect on high-dose intravenous immunoglobulin: Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 84:1974-1981, 1989
32. SCHULZE M, BAKER PJ, PERKINSON DT, JOHNSON RJ, OCHI RF, STAHL RA, COUSER WG: Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. Kidney Int 35:60-68, 1989
33. BAKER PJ, OCHI RF, SCHULZE M, JOHNSON RJ, CAMPBELL C, COUSER WG: Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol 135:185-194, 1989
34. BRADLEY GM, BENSON ES: Examination of the urine, Todd-Stanford, in Clinical Diagnosis by Laboratory Methods (15th ed), edited by DAVIDSON I, HENRY JB, Philadelphia, WB Saunders, 1974
35. RUSSO C, CALLEGARO L, LANZA E, FERRONE S: Purification of IgG monoclonal antibody by caprylic acid precipitation. J Immunol Meth 65:269-271, 1983
36. SCHWARTZ RS: Overview of the biochemistry and safety of a new native intravenous gamma globulin, IGIV, pH 4.25. Am J Med 83(Suppl 4A):46-51, 1987
37. HEREMANS JF: Antigen titration by simple radial immunodiffusion in plates, in Methods in Immunology and Immunochemistry (vol III), edited by WILLIAMS CA, CHASE MW, New York, Academic Press, 1971
38. SCHULZE M, PRUCHNO CJ, BURNS M, BAKER PJ, JOHNSON RJ, COUSER WG: Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. Am J Pathol 142:179-187, 1993
39. BRANDT J, PIPPIN J, SCHULZE M, HÄNSCH GM, ALPERS CE, JOHNSON RJ, GORDON K, COUSER WG: Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 49:335-343, 1996
40. NELSON RA, JENSEN J, GIGLI I, TAMURA N: Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry 3:111-135, 1966
41. PRUCHNO CJ, BURNS M, SCHULZE M, JOHNSON RJ, BAKER PJ, ALPERS CE, COUSER WG: Urinary excretion of the C5b-9 membrane attack complex of complement is a marker of immune disease activity in autologous immune complex nephritis. Am J Pathol 138:203-211, 1991
42. JOHNSON RJ, YAMABE H, CHEN YP, CAMPBELL C, GORDON K, BAKER P, LOVETT D, COUSER WG: Glomerular epithelial cells secrete a glomerular basement membrane-degrading metalloproteinase. J Am Soc Nephrol 2:1388-1397, 1992
43. RICHARDSON CA, GORDON KL, COUSER WG, BOMSZTYK K: IL-1β increases laminin B2 chain mRNA levels and activates NF-κB in rat glomerular epithelial cells. Am J Physiol 268:F273-F278, 1995
44. FLOEGE J, JOHNSON RJ, GORDON K, YOSHIMURA A, CAMPBELL C, IRUELA-ARISPE L, ALPERS CE, COUSER WG: Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. Kidney Int 42:573-585, 1992
45. IMBACH P, BARANDUN S, D'APUZZO V, BAUMGARTNER C, HIRT A, MORELL A, ROSSI E, SCHONI M, VEST M, WAGNER HP: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228-1231, 1981
46. JORDAN SC, TOYODA M: Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. Clin Exp Immunol 97(Suppl 1):31-38, 1994
47. SMILEY JD, TALBERT MG: High-dose intravenous gamma globulin therapy: How does it work? Am J Med Sci 309:295-303, 1995
48. REMUZZI G: HUS and TTP: Variable expression of a single entity. Kidney Int 32:292-308, 1987
49. MIYAKAWA S, UENO T, MOCHIZUKI H, ISHIDOYA N, TAHARA H, MURAMATSU Y, FUJISAWA Y, USUI N, AKATSUKA J, AIZAWA S: High dose intravenous gammaglobulin therapy against pediatric intractable renal diseases. Jikeikai Med J 33:241-252, 1986
50. EMERSON JTE, COLLINS MS, BUDINGER MD: Use of a new, low-pH immunoglobulin G preparation during episodes of bacteremia in the rat. Rev Infect Dis 8(Suppl 4):S409-S419, 1986
51. COUSER WG, SCHULZE M, PRUCHNO CJ: Role of C5b-9 in experimental membranous nephropathy. Nephrol Dial Transplant 7:S25-S31, 1992
52. HEBERT LA, COSIO FG, BIRMINGHAM DJ: The role of complement system in renal injury. Semin Nephrol 12:408-427, 1992
53. CYBULSKY AV, RENNKE HG, FEINTZEIG ID, SALANT DJ: Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy. J Clin Invest 71: 1096-1107, 1986
54. FRIES LF, GAITHER TA, HAMMER CH, FRANK MM: C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factor H and I. J Exp Med 160:1640-1655, 1984
55. GADD KJ, REID KBM: The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J 195:471-480, 1981
56. BROWN E, BERGER JM, JOINER KA, FRANK MM: Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. Infect Immun 42:594-598, 1983
57. JACOBS RJ, REICHLIN M: C3-bearing immunoglobulin in human serum. J Immunol 130:2775-2781, 1983
58. 125I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity. Clin Immunol Immunopathol 34:227-236, 1985
59. SALANT DJ, BELOK S, MADAIO MP, COUSER WG: A new role for complement in experimental membranous nephropathy in rats. J Clin Invest 66:1339-1350, 1980
60. COUSER WG, JOHNSON RJ, YOUNG BA, YEH CG, TOTH CA, RUDOLPH AR: The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 5:1888-1894, 1995
61. TACK BF: The β-Cys-γ-Glu thioester bond in human C3. C4, and α2-macroglobulin. Springer Semin Immunopathol 6:259-282, 1983
62. PANGBURN MK, MULLER-EBERHARDT HJ: The C3 convertase of the alternative pathway of human complement. Enzymatic properties of the biomolecular proteinase. Biochem J 235:723-730, 1986
63. MULLER-EBERHARDT HJ: Complement: Chemistry and pathways, in Inflammation: Basic Principles and Clinical Correlates, edited by GALLIN JI, GOLDSTEIN IM, SYNDERMAN R, New York, Raven Press, 1988
64. MOLLNES TE, LACHMANN PJ: Regulation of complement. Scand J Immunol 27:127-142, 1988
65. HÄNSCH GM, BETZ M, GUNTHER J, ROTHER KO, STERZEL B: The complement membrane attack complex stimulates the prostanoid production of cultured glomerular epithelial cells. Int Arch Allergy Appl Immunol 85:87-93, 1988
66. CYBULSKY AV, SALANT DJ, QUIGG RJ, BADALAMENTI J, BONVENTREJV: Complement C5b-9 complex activates phospholipases in glomerular epithelial cells. Am J Physiol 257:F826-F836, 1989
67. CYBULSKY AV, BONVENTRE JV, QUIGG RJ, LIEBERTHAL W, SALANT DJ: Cytosolic calcium and protein kinase C reduce complement-mediated glomerular epithelial cell injury. Kidney Int 38:803-811, 1990
68. WAGNER C, BRAUNGER M, BEER M, ROTHER K, HÄNSCH GM: Induction of matrix protein synthesis in human glomerular mesangial cells by the terminal complement complex. Exp Nephrol 2:51-56, 1994
69. QUIGG RJ, CYBULSKY AV, JACOBS JB, SALANT DJ: Anti-Fxla produces complement-dependent cytotoxicity of glomerular epithelial cells. Kidney Int 34:43-52, 1988